Bali V, Schelfhout J, Sher MR, Tripathi Peters A, Patel GB, Mayorga M, Goss D, Romano (DeMuro) C. Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis. Ther Adv Respir Dis. 2024 Mar 19;18:175346662. doi: 10.1177/17534666241236025
Zhang Y, Mayorga ME, Ivy J, Hassmiller Lich K, Swann JL. Modeling the impact of nonpharmaceutical interventions on COVID-19 transmission in K-12 schools. MDM Policy Pract. 2022 Dec 3;7(2):238146832. doi: 10.1177/23814683221140866
Sutphin J, DiSantostefano RL, Leach C, Hauber B, Mansfield C. Exploring decisional conflict with measures of numeracy and optimism in a stated preference survey. MDM Policy Pract. 2021 Nov 13;6(2):238146832. doi: 10.1177/23814683211058663
Schmitt CL, Allen JA, Kosa KM, Curry LE. Support for a ban on tobacco powerwalls and other point-of-sale displays: findings from focus groups. Health Educ Res. 2015 Feb;30(1):98-106. doi: 10.1093/her/cyu046.
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Dine JL, Schneider MK, Stewart BR, Armer JM. Learning from traditional healers in South Africa. J Lymphoedema. 2009;4(2):10-6.